Implementation of pre‐emptive testing of a pharmacogenomic panel in clinical practice: Where do we stand?

Abstract excerpt

Adverse drug reactions (ADRs) account for a large proportion of hospitalizations among adults and are more common in multimorbid patients, worsening clinical outcomes and burdening healthcare resources. Over the past decade, pharmacogenomics has been developed as a practical tool for optimizing treatment outcomes by mitigating the risk of ADRs. Some single-gene reactive tests are already used in clinical...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Antibiotics Pharmacokinetics and Efficacy
• Share to Pharmaceutical studies and practices
• Share to Pharmacogenetics and Drug Metabolism